Medical Condition News

RSS

Consuming variety of fruits, vegetables may decrease squamous cell lung cancer risk: Study

Adding a variety of vegetables to one's diet may help decrease the chance of getting lung cancer, and adding a variety of fruits and vegetables may decrease the risk of squamous cell lung cancer, especially among smokers.

2 Sep 2010

Sangart reports positive MP4OX Phase IIa study data in severely injured trauma patients with hemorrhagic shock

Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. The study demonstrated that MP4OX, when given in addition to standard of care, was effective at decreasing lactate levels in treated patients.

2 Sep 2010

DASH eating plan reduces heart disease risk in African Americans: Study

A new study suggests yet another reason for Americans to abandon their current fatty diets in favor of one rich in fruits and vegetables and low in saturated fat. Choosing these healthier options appears to significantly reduce the long-term risk of heart disease in patients with mildly elevated blood pressure, particularly African Americans.

2 Sep 2010

USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Strattera ®, atomoxetine hydrochloride capsules.

2 Sep 2010

FDA approves LUMIGAN eye drops for intraocular pressure reduction in open-angle glaucoma patients

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

2 Sep 2010

Event Pulse report reveals impact of new therapies on MS drug market

The study titled Event Pulse Preview: Multiple Sclerosis shows that 84% of neurologists expect to prescribe Gilenia for some MS patients if approved, but prescribing will likely be limited to second- or third-line therapy until concerns about safety and monitoring requirements are resolved.

1 Sep 2010

Parkinson’s disease discoveries

Genes that affect the immune system and link it to Parkinson’s disease have been uncovered. This paves the way for new drug development in Parkinson’s disease – a serious, degenerative disease of the nerves that leads to tremors and muscle stiffness and eventually complete loss of movements. There is currently no cure for PD.

31 Aug 2010

Sangart reports positive data from MP4OX Phase IIa study in trauma patients

31 Aug 2010

pSivida announces FDA Priority Review status for Iluvien NDA

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME).

31 Aug 2010

Stromedix's STX-100 receives orphan drug status from FDA for treatment of IPF

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis, a debilitating and almost uniformly fatal disease in which patients experience progressive difficulty breathing due to fibrosis (scarring) of the lung.

31 Aug 2010

First mind controlled prosthesis

Christian Kandlbauer, who lost both of his arms in a high voltage accident, uses a unique development which until recently sounded almost like science fiction: An arm prosthesis, the first of its kind in the world, which he controls solely through the power of his mind.

31 Aug 2010

Release of cortisol with fixed regularity can help cope with stress better

If your body releases cortisol with fixed regularity then you can cope with stress better, says NWO-funded researcher Angela Sarabdjitsingh. She investigated the rhythm of corticosterone production in rats. This rat hormone is comparable to the human stress hormone cortisol. Rats deal considerably less well with stress if the pattern of corticosterone release changes. An irregular release pattern is a characteristic of chronic stress and stress-related diseases. It might therefore be possible to treat these by restoring the rhythm.

31 Aug 2010

GP training may accelerate improvement in physical functioning for patients with somatoform disorder

In this pragmatic cluster-randomised controlled trial the investigators aimed to test the effect of a training programme for general practitioners (GPs) in the treatment of functional somatic symptoms (FSS). Results indicate that GP training may accelerate improvement in physical functioning for patients with somatoform disorder. However, the effect is small and may not be clinically significant.

31 Aug 2010

Royal Caribbean encourages consumers to use their hard-earned vacation days

Over-worked, over-tired and stressed-out workers have one more thing to worry about this coming Labor Day – how many vacation days they could potentially be losing this year. And if The President of the United States, who just returned from a respite on Martha's Vineyard, can still find time, then shouldn't everyone?

31 Aug 2010

Incidence of acute myocardial infarction increases among young Italian women: Study

The incidence of acute myocardial infarction in Italy sharply increased, particularly among young women, between the years 2001 and 2005, according to a comprehensive study funded by the Human Health Foundation, a nonprofit Italian charity for biomedical research and health education in Spoleto, Italy. The results were published in Aging Clinical Experimental Research.

31 Aug 2010

Sonomax and Solar Ear Brazil sign Term Sheet to develop hearing aids

Sonomax Technologies Inc. is pleased to announce that it has signed a Term Sheet with Brazil based Solar Ear. Under the terms of the agreement, Sonomax will adapt it's V4 earmold so that it can be paired with Solar Ear's BTE (Behind-the-ear) hearing aids and supported by Solar Ear's unique solar chargers. The hearing aids resulting from the marriage of these leading edge technologies will be for distribution throughout the developing world.

31 Aug 2010

ESC issues revised practice guidelines for management of AF

The European Society of Cardiology today issued revised practice guidelines for the management of atrial fibrillation, including guidance on the role of a novel oral treatment, dabigatran etexilate, for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

31 Aug 2010

Study on conflict between capacity to pay and need for health care

Cardiovascular disease (CVD) in all its forms is the biggest cause of death across Europe. Although there is little doubt that better focus on prevention can lessen its impact, we are left with a series of fundamental questions to what extent can the impact be reduced, and at what cost. And are the health benefits of prevention worth the investment. The EUROASPIRE III health economics study aims to find out.

31 Aug 2010

Halozyme identifies strategy to reintroduce HYLENEX

Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.

31 Aug 2010

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch."

31 Aug 2010